🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11 results for “Rein Therapeutics” Clear

  1. Identical to the Test product, XGEVA 120 mg solution for injection

    Rein Therapeutics

    Prevention of breast cancer in women with a BRCA1 germline mutation

    phase 3 small molecule active

    1 trial

  2. Nivolumab

    Rein Therapeutics

    Metastatic Kidney Cancer

    phase 3 small molecule active

    1 trial

  3. TAMOXIFEN, LETROZOLE, ANASTROZOLE, FULVESTRANT, LEUPRORELIN, OXYBUTYNIN, GOSERELIN, VENLAFAXINE, LEUPRORELIN, GOSERELIN, EXEMESTANE, VENLAFAXINE

    Rein Therapeutics

    Breast cancer

    phase 3 small molecule active

    1 trial

  4. LTI-01

    Rein Therapeutics

    Pleural Effusion

    phase 2 small molecule completed

    1 trial

  5. LTI-03

    Rein Therapeutics

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  6. LTI-03, The placebo is InhaLac® 500 (micronized lactose monohyrdate).

    Rein Therapeutics

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  7. Lynparza 100 mg film-coated tablets, CYCLOPHOSPHAMIDE, Lynparza 150 mg film-coated tablets, DOCETAXEL, DOXORUBICIN, CARBOPLATIN, EPIRUBICIN

    Rein Therapeutics

    Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)

    phase 2 small molecule active

    1 trial

  8. ORSERDU 86 mg film-coated tablets, LETROZOLE , -, ORSERDU 345 mg film-coated tablets, Kisqali 200 mg film-coated tablets, EXEMESTANE , ANASTROZOLE

    Rein Therapeutics

    endocrine-responsive HER2-negative early breast cancer

    phase 2 small molecule active

    1 trial

  9. Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)

    Rein Therapeutics

    Idiopathic Pulmonary Fibrosis

    phase 1 small molecule completed

    1 trial

  10. LTI-03

    Rein Therapeutics

    Idiopathic Pulmonary Fibrosis

    phase 1 small molecule completed

    1 trial

  11. SODIUM CHLORIDE, Ondansetron Morningside 4 mg orodispergeerbare tabletten, Ondansetron 2 mg/ml Solution for Injection, Ketanest® S 5 mg/ml - Ampullen

    Rein Therapeutics

    Endometriosis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources